演題詳細

ポスター / Poster

ポスター 9 (Poster 9) :CML:臨床1 (CML:Clinical Research 1)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
田中 英夫 (Hideo Tanaka):1
1:広島市立安佐市民病院 血液内科
 
前へ戻る

Characteristics of patients with chronic myeloid leukemia and treatment outcomes at our institution

演題番号 : PS-1-62

飯野 昌樹 (Masaki Iino):1

1:Dept. of Medical Oncology, Yamanashi Prefectural Central Hospital, Kofu, Japan、2:Ambulatory Therapeutic Cancer Center, Yamanashi Prefectural Central Hospital, Kofu, Japan

 

[Background] Chronic myeloid leukemia (CML) treatment has benefited significantly from the introduction of tyrosine-kinase inhibitors (TKIs), with 3 TKIs currently available in Japan. To confirm their clinical efficacy, we retrospectively analyzed CML patients treated with TKIs at our institution. [Method] We evaluated CML patients treated at our institution between April 2002 and June 2012. Overall survival (OS), progression-free survival (PFS), and the cumulative incidence of response were estimated by the Kaplan-Meier method and compared with log-rank test. [Results] A total of 38 patients were enrolled, with a male:female ratio of 27:11, and median age of 65 years (range, 23-87). All patients were in the chronic phase at diagnosis. OS and PFS at 5 years were 90% and 86%, respectively. Initially, 26 patients received standard-dose imatinib (SD-IM; 300-400 mg/day), 7 received low-dose IM (LD-IM; 100-200 mg/day), and 5 received a standard dose of a second generation TKI (2nd TKI), either nilotinib or dasatinib. Two patients treated with LD-IM died from progression to blast crisis. Nine patients treated with IM were switched to 2nd TKIs due to intolerance or insufficient efficacy. The 2-year OS, PFS, and median time to complete cytogenetic response (CCyR) were significantly better in the 2nd TKI group than the SD-IM or LD-IM groups (CCyR: 3.0 mo, 5.2 mo, not reached; OS: 100%, 96%, 86%; PFS: 100%, 96%, 86%, respectively). [Conclusion]This analysis supports the excellent efficacy of 2nd TKIs, which should be administered at sufficient doses for favorable survival outcomes.

前へ戻る